GlassScriptPhysician profile
Anne M Floyd
NPI 1023454410
$10,730.78
in general payments reported to CMS, 2019-2025
32 companies · $1,439 in 2025
The $1,439 reported for 2025 was more than what 84% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,446 · 2020: $764 · 2021: $1,988 · 2022: $2,214 · 2023: $1,761 · 2024: $1,118 · 2025: $1,439.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,318.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,317.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,677.12 | 2021-2025 | Clareon, Clareon Panoptix Pro, Unity |
| Glaukos Corporation | $1,475.24 | 2020-2025 | Idosetr, Istent Infinite, Idose |
| Bausch & Lomb Americas INC. | $912.29 | 2022-2025 | Stellaris, Amvisc Plus, Vyzulta |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $881.11 | 2019-2021 | |
| Johnson & Johnson Surgical Vision, INC. | $724.58 | 2021-2023 | Tecnis Iol, Tecnis Iol, Veritas Vision System |
| Abbvie INC. | $682.52 | 2022-2025 | |
| Allergan, INC. | $650.44 | 2019-2022 | |
| Aerie Pharmaceuticals, INC. | $402.68 | 2019-2021 | |
| Sight Sciences, INC. | $400.23 | 2021-2025 | Omni Surgical System |
| Horizon Therapeutics Plc | $322.60 | 2019-2023 | Tepezza |
| Sun Pharmaceutical Industries INC. | $319.85 | 2019-2023 | Cequa, Bromsite, Xelpros |
| Novartis Pharmaceuticals Corporation | $307.43 | 2019-2023 | |
| Dompe US, INC. | $283.12 | 2019-2025 | Oxervate |
| Mallinckrodt Enterprises LLC | $243.97 | 2019 | |
| Kala Pharmaceuticals, INC. | $243.90 | 2019-2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harrow Eye, LLC | $187.93 | 2025 | Verkazia, Natacyn, Flarex |
| Rxsight INC | $149.98 | 2023 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Injector Cartridge |
| Nova Eye, INC. | $133.21 | 2024 | |
| Ivantis, INC | $116.03 | 2020 | |
| Mallinckrodt Hospital Products INC. | $101.95 | 2020-2024 | Acthar |
| Tarsus Pharmaceuticals, INC. | $83.28 | 2024 | Xdemvy |
| Genentech USA, INC. | $81.04 | 2022 | |
| Oyster Point Pharma, INC. | $68.92 | 2022-2025 | Tyrvaya, Ryzumvi |
| Rayner Intraocular Lenses Limited | $60.32 | 2024 | Omidria, Rayone Aspheric, Rayone Emv |
| Biotissue Holdings INC. | $46.25 | 2021-2023 | |
| Shire North American Group INC | $38.50 | 2019 | |
| Akorn Operating Company LLC | $36.84 | 2021 | |
| Amgen INC. | $25.76 | 2024 | Tepezza |
| Astellas Pharma US INC | $20.89 | 2023 | Izervay |
| Travere Therapeutics, INC. | $18.86 | 2022 | |
| Thea Pharma INC. | $17.72 | 2023 | |
| Ocular Therapeutix, INC. | $16.22 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anne Floyd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.